Metformin confers risk reduction for developing hepatocellular carcinoma recurrence after liver resection

The Preference for Anterior Approach Major Hepatectomy

(2015) Kun-Ming Chan et al.   MEDICINE

Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies

(2012) Hsiao-Ping Chen et al.   GUT

Risk of Hepatocellular Carcinoma in Diabetic Patients and Risk Reduction Associated With Anti-Diabetic Therapy: A Population-Based Cohort Study

(2011) Shih-Wei Lai et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Long-Term Results of a Randomized, Observation-Controlled, Phase III Trial of Adjuvant Interferon Alfa-2b in Hepatocellular Carcinoma After Curative Resection

(2011) Li-Tzong Chen et al.   ANNALS OF SURGERY

Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals

(2011) Meei-Shyuan Lee et al.   BMC CANCER

Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1

(2011) I. Ben Sahra et al.   CANCER RESEARCH

Associations of diabetes mellitus with site-specific cancer mortality in the Asia-Pacific region

(2010) E. K. K. Lam et al.   ANNALS OF ONCOLOGY

Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma

(2010) Manal M. Hassan et al.   CANCER

Diabetes and Cancer: A consensus report

(2010) E. Giovannucci et al.   DIABETES CARE

Substantially increased risk of cancer in patients with diabetes mellitus

(2010) Hiroshi Noto et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease

(2010) Valter Donadon et al.   LIVER INTERNATIONAL

Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus

(2008) Bart J. Veldt et al.   HEPATOLOGY

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level

(2008) I Ben Sahra et al.   ONCOGENE